Experimental cancer treatment
Experimental cancer treatments are medical therapies intended or claimed to treat cancer (see also tumor) by improving on, supplementing or replacing conventional methods (surgery, chemotherapy, radiation, and immunotherapy).
The entries listed below vary between theoretical therapies to unproven controversial therapies. Many of these treatments are alleged to help against only specific forms of cancer. It is not a list of treatments widely available at hospitals.
- 1 Studying treatments for cancer
- 2 Bacterial treatments
- 3 Drug therapies
- 4 Gene therapy
- 5 Epigenetic Options
- 6 Telomerase therapy
- 7 Radiation therapies
- 8 Electromagnetic treatments
- 9 Complementary and alternative treatments
- 10 References
- 11 External links
Studying treatments for cancer
The twin goals of research are to determine whether the treatment actually works (called efficacy) and whether it is sufficiently safe. Regulatory processes attempt to balance the potential benefits with the potential harms, so that people given the treatment are more likely to benefit from it than to be harmed by it.
Medical research for cancer begins much like research for any disease. In organized studies of new treatments for cancer, the pre-clinical development of drugs, devices, and techniques begins in laboratories, either with isolated cells or in small animals, most commonly rats or mice. In other cases, the proposed treatment for cancer is already in use for some other medical condition, in which case more is known about its safety and potential efficacy.
Clinical trials are the study of treatments in humans. The first-in-human tests of a potential treatment are called Phase I studies. Early clinical trials typically enroll a very small number of patients, and the purpose is to identify major safety issues and the maximum tolerated dose, which is the highest dose that does not produce serious or fatal adverse effects. The dose given in these trials may be far too small to produce any useful effect. In most research, these early trials may involve healthy people, but cancer studies normally enroll only people with relatively severe forms of the disease in this stage of testing. On average, 95% of the participants in these early trials receive no benefit, but all are exposed to the risk of adverse effects. Most participants show signs of optimism bias (the irrational belief that they will beat the odds).
Later studies, called Phase II and Phase III studies, enroll more people, and the goal is to determine whether the treatment actually works. Phase III studies are frequently randomized controlled trials, with the experimental treatment being compared to the current best available treatment rather than to a placebo. In some cases, the Phase III trial provides the best available treatment to all participants, in addition to some of the patients receiving the experimental treatment.
Chemotherapeutic drugs have a hard time penetrating tumors to kill them at their core because these cells may lack a good blood supply. Researchers have been using anaerobic bacteria, such as Clostridium novyi, to consume the interior of oxygen-poor tumours. These should then die when they come in contact with the tumour's oxygenated sides, meaning they would be harmless to the rest of the body. A major problem has been that bacteria do not consume all parts of the malignant tissue. However, combining the therapy with chemotheraputic treatments can help to solve this problem.
Another strategy is to use anaerobic bacteria that have been transformed with an enzyme that can convert a non-toxic prodrug into a toxic drug. With the proliferation of the bacteria in the necrotic and hypoxic areas of the tumour, the enzyme is expressed solely in the tumour. Thus, a systemically applied prodrug is metabolised to the toxic drug only in the tumour. This has been demonstrated to be effective with the nonpathogenic anaerobe Clostridium sporogenes.
HAMLET (human alpha-lactalbumin made lethal to tumor cells)
HAMLET (human alpha-lactalbumin made lethal to tumor cells) is a molecular complex derived from human breast milk that kills tumor cells by a process resembling programmed cell death (apoptosis). It has been tested in humans with skin papillomas and bladder cancer.
Dichloroacetate (DCA) has been found to shrink tumors in vivo in rats, and has a plausible scientific mechanism: DCA appears to reactivate suppressed mitochondria in some types of oxygen-starved tumor cells, and thus promotes apoptosis. Because it was tested for other conditions, DCA is known to be relatively safe, available, and inexpensive, and it can be taken by mouth as a pill, which is convenient. Five patients with brain cancer have been treated with DCA in a clinical trial, and the authors say that the lives of four were 'probably' extended. However, without a large controlled trial it is impossible to say whether the drug is truly effective against cancer.
Quercetin is a principal flavonoid compound and an excellent free-radical-scavenging antioxidant that promotes apoptosis. In vitro it shows some antitumor activity in oral cancer and leukemia. Cultured skin and prostate cancer cells showed significant mortality (compared to nonmalignant cells) when treated with a combination of quercetin and ultrasound. Note that ultrasound also promotes topical absorption by up to 1,000 times, making the use of topical quercetin and ultrasound wands an interesting proposition.
High dietary intake of fruits and vegetables is associated with reduction in cancer, and some scientists, such as Gian Luigi Russo at the Institute of Food Sciences in Italy, suspect quercetin may be partly responsible. Research shows that quercetin influences cellular mechanisms in vitro and in animal studies. According to the American Cancer society, "there is no reliable clinical evidence that quercetin can prevent or treat cancer in humans".
Insulin potentiation therapy
Insulin potentiation therapy is practice of injecting insulin, usually alongside conventional cancer drugs, in the belief that this improves the overall effect of the treatment. Quackwatch state: "Insulin Potentiation Therapy (IPT) is one of several unproven, dangerous treatments that is promoted by a small group of practitioners without trustworthy evidence that it works."
Drugs that restore p53 activity
Several drug therapies are being developed based on p53, the tumour suppressor gene that protects the cell in response to damage and stress. It is analogous to deciding what to do with a damaged car: p53 brings everything to a halt, and then decides whether to fix the cell or, if the cell is beyond repair, to destroy the cell. This protective function of p53 is disabled in most cancer cells, allowing them to multiply without check. Restoration of p53 activity in tumours (where possible) has been shown to inhibit tumour growth and can even shrink the tumour.
As p53 protein levels are usually kept low, one could block its degradation and allow large amounts of p53 to accumulate, thus stimulating p53 activity and its antitumour effects. Drugs that utilize this mechanism include nutlin and MI-219, which are both in phase I clinical trials. There are also other drugs that are still in the preclinical stage of testing, such as RITA and MITA.
BI811283 is a small molecule inhibitor of the aurora B kinase protein being developed by Boehringer Ingelheim for use as an anti-cancer agent. BI 811283 is currently in the early stages of clinical development and is undergoing first-in-human trials in patients with solid tumors and Acute Myeloid Leukaemia.
Introduction of tumor suppressor genes into rapidly dividing cells has been thought to slow down or arrest tumor growth. Adenoviruses are a commonly utilized vector for this purpose. Much research has focused on the use of adenoviruses that cannot reproduce, or reproduce only to a limited extent, within the patient to ensure safety via the avoidance of cytolytic destruction of noncancerous cells infected with the vector. However, new studies focus on adenoviruses that can be permitted to reproduce, and destroy cancerous cells in the process, since the adenoviruses' ability to infect normal cells is substantially impaired, potentially resulting in a far more effective treatment. Another use of gene therapy is the introduction of enzymes into these cells that make them susceptible to particular chemotherapy agents; studies with introducing thymidine kinase in gliomas, making them susceptible to aciclovir, are in their experimental stage.
Epigenetics is the study of heritable changes in gene activity that are not caused by changes in the DNA sequence, often a result of environmental or dietary damage to the histone receptors within the cell. Current research has shown that epigenetic pharmaceuticals could be a putative replacement or adjuvant therapy for currently accepted treatment methods such as radiation and chemotherapy, or could enhance the effects of these current treatments. It has been shown that the epigenetic control of the proto-onco regions and the tumor suppressor sequences by conformational changes in histones directly affects the formation and progression of cancer. Epigenetics also has the factor of reversibility, a characteristic that other cancer treatments do not offer.
Because most malignant cells rely on the activity of the protein telomerase for their immortality, it has been proposed that a drug that inactivates telomerase might be effective against a broad spectrum of malignancies. At the same time, most healthy tissues in the body express little if any telomerase, and would function normally in its absence. Currently, inositol hexaphosphate, which is available over-the-counter, is undergoing testing in cancer research due to its telomerase-inhibiting abilities.
A number of research groups have experimented with the use of telomerase inhibitors in animal models, and as of 2005 and 2006 phase I and II human clinical trials are underway. Geron Corporation is currently conducting two clinical trials involving telomerase inhibitors. One uses a vaccine (GRNVAC1) and the other uses a lipidated oligonucleotide(GRN163L).
Photodynamic therapy (PDT) is generally a non-invasive treatment using a combination of light and a photosensitive drug, such as 5-ALA, Foscan, Metvix, Tookad, WST09, WST11, Photofrin, or Visudyne. The drug is triggered by light of a specific wavelength.
Localized and whole-body application of heat has been proposed as a technique for the treatment of malignant tumours. Intense heating will cause denaturation and coagulation of cellular proteins, rapidly killing cells within a tumour.
More prolonged moderate heating to temperatures just a few degrees above normal (39,5 °C) can cause more subtle changes. A mild heat treatment combined with other stresses can cause cell death by apoptosis. There are many biochemical consequences to the heat shock response within the cell, including slowed cell division and increased sensitivity to ionizing radiation therapy. The purpose of overheating the tumor cells is to create a lack of oxygen so that the heated cells become overacidified, which leads to a lack of nutrients in the tumor. This in turn disrupts the metabolism of the cells so that cell death (apoptosis) can set in. In certain cases chemotherapy or radiation that has previously not had any effect can be made effective. Hyperthermia alters the cell walls by means of so-called heat shock proteins. The cancer cells then react very much more effectively to the cytostatics and radiation. If hyperthermia is used conscientiously it has no serious side effects.
There are many techniques by which heat may be delivered. Some of the most common involve the use of focused ultrasound (FUS or HIFU), microwave heating, induction heating, magnetic hyperthermia, and direct application of heat through the use of heated saline pumped through catheters. Experiments with carbon nanotubes that selectively bind to cancer cells have been performed. Lasers are then used that pass harmlessly through the body, but heat the nanotubes, causing the death of the cancer cells. Similar results have also been achieved with other types of nanoparticles, including gold-coated nanoshells and nanorods that exhibit certain degrees of 'tunability' of the absorption properties of the nanoparticles to the wavelength of light for irradiation. The success of this approach to cancer treatment rests on the existence of an 'optical window' in which biological tissue (i.e., healthy cells) are completely transparent at the wavelength of the laser light, while nanoparticles are highly absorbing at the same wavelength. Such a 'window' exists in the so-called near-infrared region of the electromagnetic spectrum. In this way, the laser light can pass through the system without harming healthy tissue, and only diseased cells, where the nanoparticles reside, get hot and are killed.
One of the challenges in thermal therapy is delivering the appropriate amount of heat to the correct part of the patient's body. A great deal of current research focuses on precisely positioning heat delivery devices (catheters, microwave, and ultrasound applicators, etc.) using ultrasound or magnetic resonance imaging, as well as of developing new types of nanoparticles that make them particularly efficient absorbers while offering little or no concerns about toxicity to the circulation system. Clinicians also hope to use advanced imaging techniques to monitor heat treatments in real time—heat-induced changes in tissue are sometimes perceptible using these imaging instruments. In magnetic hyperthermia or magnetic fluid hyperthermia method, it will be easier to control temperature distribution by controlling the velocity of ferrofluid injection and size of magnetic nanoparticles.
Non-invasive cancer treatment
This preclinical treatment involves using radio waves to heat up tiny metals that are implanted in cancerous tissue. Gold nanoparticles or carbon nanotubes are the most likely candidate. Promising preclinical trials have been conducted, although clinical trials may not be held for another few years.
Another method that is entirely non-invasive referred to as Tumor Treating Fields has already reached clinical trial stage in many countries. The concept applies an electric field through a tumour region using electrodes external to the body. Successful trials have shown the process effectiveness to be greater than chemotherapy and there are no side-effects and only negligible time spent away from normal daily activities. This treatment is still in very early development stages for many types of cancer.
High-intensity focused ultrasound (HIFU) is still in investigatory phases in many places around the world. In China it has CFDA approval and over 180 treatment centres have been established in China, Hong Kong, and Korea. HIFU has been successfully used to treat cancer to destroy tumours of the bone, brain, breast, liver, pancreas, rectum, kidney, testes, and prostate. Several thousand patients have been treated with various types of tumours. HIFU has CE approval for palliative care for bone metastasis. Experimentally, palliative care has been provided for cases of advanced pancreatic cancer. High-energy therapeutic ultrasound could increase higher-density anti-cancer drug load and nanomedicines to target tumor sites by 20x fold higher than traditional target cancer therapy.
Complementary and alternative treatments
Complementary and alternative medicine (CAM) treatments are the diverse group of medical and healthcare systems, practices, and products that are not part of conventional medicine and have not been proven to be effective. Complementary medicine usually refers to methods and substances used along with conventional medicine, while alternative medicine refers to compounds used instead of conventional medicine. CAM use is common among people with cancer.
Most complementary and alternative medicines for cancer have not been rigorously studied or tested. Some alternative treatments that have been proven ineffective continue to be marketed and promoted.
- Chen, Pauline W. (3 March 2011). "When Optimism Is Unrealistic". The New York Times.
- Mengesha (2009). "Clostridia in Anti-tumor Therapy". Clostridia: Molecular Biology in the Post-genomic Era. Caister Academic Press. ISBN 978-1-904455-38-7.
- Hallgren O; Aits S; Brest P; Gustafsson L; Mossberg AK; Wullt B; Svanborg C. (2008). "Apoptosis and tumor cell death in response to HAMLET (human alpha-lactalbumin made lethal to tumor cells)". Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology. 606: 217–240. doi:10.1007/978-0-387-74087-4_8. ISBN 978-0-387-74086-7. PMID 18183931.
- Michelakis ED, Webster L, Mackey JR (October 2008). "Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer". Br. J. Cancer. 99 (7): 989–94. doi:10.1038/sj.bjc.6604554. PMC . PMID 18766181.
- Michelakis, E. D.; Sutendra, G.; Dromparis, P.; Webster, L.; Haromy, A.; Niven, E.; Maguire, C.; Gammer, T. L.; Mackey, J. R.; Fulton, D.; Abdulkarim, B.; McMurtry, M. S.; Petruk, K. C. (12 May 2010). "Metabolic Modulation of Glioblastoma with Dichloroacetate". Science Translational Medicine. 2 (31): 31ra34–31ra34. doi:10.1126/scitranslmed.3000677. PMID 20463368.
- Sutendra, G; Michelakis, ED (2013). "Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology.". Frontiers in Oncology. 3: 38. doi:10.3389/fonc.2013.00038. PMID 23471124.
- "Cancer drug resurfaces and threatens false optimism". New Scientist. Retrieved 16 May 2011.
- "Potential cancer drug DCA tested in early trials". Cancer Research UK.
- Brüning, A (Dec 11, 2012). "Inhibition of mTOR Signaling by Quercetin in Cancer Treatment and Prevention.". Anti-cancer agents in medicinal chemistry. 13 (7): 1025–31. doi:10.2174/18715206113139990114. PMID 23272907.
- Gokbulut, AA; Apohan, E; Baran, Y (Feb 20, 2013). "Resveratrol and quercetin-induced apoptosis of human 232B4 chronic lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest.". Hematology (Amsterdam, Netherlands). 18 (3): 144–50. doi:10.1179/1607845412Y.0000000042. PMID 23432965.
- Chen, SF; Nien, S; Wu, CH; Liu, CL; Chang, YC; Lin, YS (March 2013). "Reappraisal of the anticancer efficacy of quercetin in oral cancer cells.". Journal of the Chinese Medical Association : JCMA. 76 (3): 146–52. doi:10.1016/j.jcma.2012.11.008. PMID 23497967.
- Paliwal S; Sundaram, J; Mitragotri, S (2005). "Induction of cancer-specific cytotoxicity towards human prostate and skin cells using quercetin and ultrasound". British Journal of Cancer. 92 (3): 499–502. doi:10.1038/sj.bjc.6602364. PMC . PMID 15685239.
- Mitragotri, Samir (1 March 2005). "Innovation: Healing sound: the use of ultrasound in drug delivery and other therapeutic applications". Nature Reviews Drug Discovery. 4 (3): 255–260. doi:10.1038/nrd1662.
- Spagnuolo, C; Russo, M; Bilotto, S; Tedesco, I; Laratta, B; Russo, GL (July 2012). "Dietary polyphenols in cancer prevention: the example of the flavonoid quercetin in leukemia.". Annals of the New York Academy of Sciences. 1259: 95–103. doi:10.1111/j.1749-6632.2012.06599.x. PMID 22758641.
- Russo, M; Spagnuolo, C; Tedesco, I; Bilotto, S; Russo, GL (Jan 1, 2012). "The flavonoid quercetin in disease prevention and therapy: facts and fancies.". Biochemical Pharmacology. 83 (1): 6–15. doi:10.1016/j.bcp.2011.08.010. PMID 21856292.
- Lam, TK; Shao, S; Zhao, Y; Marincola, F; Pesatori, A; Bertazzi, PA; Caporaso, NE; Wang, E; Landi, MT (December 2012). "Influence of quercetin-rich food intake on microRNA expression in lung cancer tissues.". Cancer Epidemiology, Biomarkers & Prevention. 21 (12): 2176–84. doi:10.1158/1055-9965.EPI-12-0745. PMID 23035181.
- "Quercetin". American Cancer Society. November 2008. Retrieved March 2014. Check date values in:
- Baratz, Robert (10 March 2007). "Why You Should Stay Away from Insulin Potentiation". Quackwatch. Retrieved March 2014. Check date values in:
- Martins CP, Brown-Swigart L, Evan GI (December 2006). "Modeling the therapeutic efficacy of p53 restoration in tumors". Cell. 127 (7): 1323–34. doi:10.1016/j.cell.2006.12.007. PMID 17182091.
- Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T (February 2007). "Restoration of p53 function leads to tumour regression in vivo". Nature. 445 (7128): 606–7. doi:10.1038/nature05541. PMID 17251932.
- Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW (February 2007). "Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas". Nature. 445 (7128): 656–60. doi:10.1038/nature05529. PMID 17251933.
- Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (December 2009). "Awakening guardian angels: drugging the p53 pathway". Nat Rev Cancer. 9 (12): 862–73. doi:10.1038/nrc2763. PMID 19935675.
- Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G (December 2004). "Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors". Nat Med. 10 (12): 1321–8. doi:10.1038/nm1146. PMID 15558054.
- Hedström E, Issaeva N, Enge M, Selivanova G (February 2009). "Tumor-specific induction of apoptosis by a p53-reactivating compound". Exp Cell Res. 315 (3): 451–61. doi:10.1016/j.yexcr.2008.11.009. PMID 19071110.
- Gürtler, U.; U. Tontsch-Grunt; M. Jarvis; S.K. Zahn; G. Boehmelt; J. Quant; G.R. Adolf; F. Solca (2010). "Effect of BI 811283, a novel inhibitor of Aurora B kinase, on tumor senescence and apoptosis". J. Clin. Oncol. 28 (15 Suppl e13632).
- Rein DT, Breidenbach M, Curiel DT (February 2006). "Current developments in adenovirus-based cancer gene therapy". Future Oncol. 2 (1): 137–43. doi:10.2217/147966184.108.40.206. PMC . PMID 16556080.
- Kanerva A; Lavilla-Alonso S; Raki M; et al. (2008). Lewin, Alfred, ed. "Systemic Therapy for Cervical Cancer with Potentially Regulatable Oncolytic Adenoviruses". PLOS ONE. 3 (8): e2917. doi:10.1371/journal.pone.0002917. PMC . PMID 18698374.
- Wang LG, Chiao JW (September 2010). "Prostate cancer chemopreventive activity of phenethyl isothiocyanate through epigenetic regulation (review)". Int. J. Oncol. 37 (3): 533–9. doi:10.3892/ijo_00000702. PMID 20664922.
- Iglesias-Linares A, Yañez-Vico RM, González-Moles MA (May 2010). "Potential role of HDAC inhibitors in cancer therapy: insights into oral squamous cell carcinoma". Oral Oncol. 46 (5): 323–9. doi:10.1016/j.oraloncology.2010.01.009. PMID 20207580.
- Li LC, Carroll PR, Dahiya R (January 2005). "Epigenetic changes in prostate cancer: implication for diagnosis and treatment". J. Natl. Cancer Inst. 97 (2): 103–15. doi:10.1093/jnci/dji010. PMID 15657340.
- Beil, Laura (Winter 2008). "Medicine's New Epicenter? Epigenetics: New field of epigenetics may hold the secret to flipping cancer's "off" switch.". CURE (Cancer Updates, Research and Education).
- Jagadeesh S, Banerjee PP (November 2006). "Inositol hexaphosphate represses telomerase activity and translocates TERT from the nucleus in mouse and human prostate cancer cells via the deactivation of Akt and PKCalpha". Biochem. Biophys. Res. Commun. 349 (4): 1361–7. doi:10.1016/j.bbrc.2006.09.002. PMID 16979586.
- Dr med Peter Wolf, 2008, Innovations in biological cancer therapy, a guide for patients and their relatives, p 31-32
- Hyperthermia - Cancer therapy hots up on physics.org
- David Templeton (18 January 2007). "Research on local man's cancer treatment idea shows it has promise". Pittsburgh Post-Gazette. Retrieved 4 November 2007.
- Gannon CJ; Cherukuri P; Yakobson BI; et al. (December 2007). "Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field". Cancer. 110 (12): 2654–65. doi:10.1002/cncr.23155. PMID 17960610.
- "The cure to cancer could be in your radio!". Winknews.com. 2007. Retrieved 1 November 2007.
- Pless M, Weinberg U (2011). "Tumor treating fields: concept, evidence and future". Expert Opin Investig Drugs. 20: 1099–106. doi:10.1517/13543784.2011.583236. PMID 21548832.
- "Tumour Treating Fields explained". ted.com. 2012. Retrieved 31 January 2012.
- Steven Mo; Constantin-C Coussios; Len Seymour; Robert Carlisle (2012). "Ultrasound-Enhanced Drug Delivery for Cancer". Expert Opinion on Drug Delivery. 9 (12): 1525–1538. doi:10.1517/17425247.2012.739603.
- Steven Mo; Robert Carlisle; Richard Laga; Rachel Myers; Susan Graham; Len Seymour; Constantin-C Coussios (2015). "Increasing the density of nanomedicines improves their ultrasound-mediated delivery to tumours". Journal of Controlled Release. 18 (10): 10–18. doi:10.1016/j.jconrel.2015.05.265.
- Davies, Angela M.; Weinberg, Uri; Palti, Yoram (2013). "Tumor treating fields: A new frontier in cancer therapy". Annals of the New York Academy of Sciences. 1291 (1): 86–95. doi:10.1111/nyas.12112. PMID 23659608.
- Cassileth BR, Deng G (2004). "Complementary and alternative therapies for cancer". Oncologist. 9 (1): 80–9. doi:10.1634/theoncologist.9-1-80. PMID 14755017.
- What Is CAM? National Center for Complementary and Integrative Health. retrieved 3 February 2008.
- Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (1 July 2000). "Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology". J. Clin. Oncol. 18 (13): 2505–14. PMID 10893280.
- Vickers A (2004). "Alternative cancer cures: "unproven" or "disproven"?". CA Cancer J Clin. 54 (2): 110–8. doi:10.3322/canjclin.54.2.110. PMID 15061600.